|
Cost US$
|
|
Cost Budesonide-Formoterol (per 120 doses)
|
$53
|
$66
|
$40
| |
|
Cost controlled (anual)
|
$416
|
$520
|
$312
|
[17]
|
|
Cost mild exacerbation (per episode)
|
$94
|
$118
|
$71
| |
|
Cost moderate exacerbation (per episode)
|
$191
|
$239
|
$143
| |
|
Cost severe exacerbation (per episode)
|
$386
|
$483
|
$290
| |
|
Utilities (anual)
|
|
Controlled asthma
|
0.92
|
1
|
0.69
| |
|
Exacerbation with OCS Burst
|
0.86
|
1
|
0,65
|
[13]
|
|
Exacerbation with ED visit
|
0,83
|
1
|
0,62
| |
|
Exacerbation with Hospitalization
|
0.74
|
0.93
|
0.56
| |
|
Budesonide + Formoterol efect
|
|
Relative risk on exacerbation rate
|
0.85
|
0.72
|
1
| |
|
Relative risk on ED visit
|
0.65
|
0.43
|
0.98
|
[9]
|
|
Adherence to as need—budesonide-formoterol
|
68%
|
85%
|
51%
|
[10]
|
|
Adherence to IC daily
|
62%
|
78%
|
47%
|
[10]
|
|
As-Needed budesonide-formoterol by Time of Day
|
0.52
|
0.65
|
0.39
| |
|
Transition probabilities
|
|
Probability controlled to OC Burst
|
0.11
|
0.14
|
0.10
| |
|
Probability OCS Burst to ED visit
|
0.02
|
0.03
|
0.02
|
[12]
|
|
Probability of ED visti to hospitalization
|
0.0117
|
0.01
|
0.01
| |
|
Asthma mortality
|
0.0000020
|
0.00
|
0.00
| |
|
Annual dicount rate
|
5%
|
6%
|
0%
| |
